CVE-2007-6763
SAS Drug Development (SDD) before 32DRG02 mishandles logout actions, which allows a user (who was previously logged in) to access resources by pressing a back or forward button in a web browser.
Does this matter?
High impact if exploited, but EPSS currently rates exploitation as unlikely (1.32%). Schedule it in the normal patch cycle and watch for a rise in EPSS or a public exploit.
Description
SAS Drug Development (SDD) before 32DRG02 mishandles logout actions, which allows a user (who was previously logged in) to access resources by pressing a back or forward button in a web browser.
- CVSS 3.0
- 8.8 HIGHCVSS:3.0/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H
- EPSS
- 1.32% probability · 71th percentile
- Public exploits
- None in Exploit-DB
- CISA KEV
- Not listed
- Weakness
- CWE-20
- Affected
- sas/sas drug development
- Source
- cve@mitre.org
EPSS 1.3% since 26 October 2026; no change recorded yet. Points are recorded when the score first appears and whenever it moves by a percentage point or more.
References
Source: NVD record, EPSS from FIRST.org, KEV from CISA, exploits from Exploit-DB. Refreshed daily. Download this record as JSON.